Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Clinical Evaluation of the GLYDe Dressing for Post-surgical Incision Care
Post Surgical Incisions From Abdominoplasty Procedures
Primary: Scar Evaluation at End of Treatment Period Comparing Treated to Standard of Care (Control) — 18.64; 50.52 score on a scale
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Phase 4 N=14 ABRA Abdominal Closure System in Open Abdomen Management
Open Abdomen
Primary: Primary Closure Rate — 75; 67 % of participants
Phase 2 N=276 In Vivo Preoperative Skin Preparation Persistence Evaluation
Bacterial Recovery of Skin Flora Post-product Application
Primary: Measurement of Skin Flora Recovery Post-prep Application — 1.39; 1.15; 1.97; 1.82 log10 CFU/cm^2 — p=0.13
Phase 3 N=326 Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
HIV Infections · Lipodystrophy
Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001
N/A N=15 DualSculpting the Abdomen Using CoolSculpting
Body Fat Disorder
Primary: Proportion of Correctly Identified Photos by Blinded Reviewers — 28 photos
Phase 2 N=60 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Abdominal Obesity · Growth Hormone Deficiency
Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2
N/A N=46 Eplerenone in HIV Associated Abdominal Fat Accumulation
HIV
Primary: Insulin Stimulated Glucose Uptake — 7.70; 8.58 mg/min per μIU/ml — p=0.71
Phase 3 N=793 Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Central Abdominal Bulging
Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397
N/A N=60 Non-Invasive Reduction of Abdominal Fat
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Phase 2 N=22 Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
N/A N=89 A Study to Evaluate Two Different Surgical Methods for Treatment for Abdominal Wall Diastasis
Abdominal Hernias and Other Abdominal Wall Conditions · Post-operative Pain · Recurrence
Primary: Recurrence of Diastasis One Year Post-operatively That Indicated by CT Scan or Clinical Investigation. — 2; 3; 26 Participants
N/A N=16 OxyGenesys Dissolved Oxygen Dressing; Abdominoplasty at Northwestern University
Wounds
Primary: Healing in Days. — 13.1; 12.5 days
N/A N=425 A Retrospective Study Evaluating the Use of Permacol Surgical Implant in the Repair of Abdominal Wall Defects
Abdominal Wall Defects
Primary: Confirmed Hernia Recurrence — 20 participants
Phase 2 N=5 Hidradenitis Suppurativa Wound Care
Hidradenitis Suppurativa (HS)
Primary: Percent Change in Wound Size — 57.2 percentage change in wound size
N/A N=36 Force Modulating Tissue Bridges for Closure of Vertical Scars in Breast Reduction
Surgical Incision
Primary: Patient and Observer Scar Assessment Scale (POSAS)- Patient Scores 12M — 1.09; 1.22; 1.3; 1.87 score on a scale
N/A N=12 Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat
Body Fat
Primary: Number of Participants Who's Abdominal Tissue Showed Necrosis or Inflammatory Immune Cell Response — 10; 0 Participants
Phase 2 N=41 Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
Scar Prevention
Primary: Expert Panel Scar Assessment Score at Week 12: Part B — 37.8; 42.1 millimeter — p=0.168
N/A N=46 RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction
Hernia, Ventral · Intestinal Fistula · Fibromatosis, Abdominal
Primary: Rate of Surgical Site Occurrences (SSOs) at 6 Week — 1; 11 event
Phase 4 N=107 Decreasing Intraoperative Skin Damage in Prone Position Surgeries
Pressure Injury
Primary: Number of Participants With Intraoperative Acquired Pressure Injuries (IAPI) — 13; 14 Participants
N/A N=45 Scleroderma ARFI Imaging of the Skin
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
N/A N=25 Quantitative Evaluation of Skin Shrinkage Caused by a Non-invasive Tightening Device
Healthy
Primary: The Change in Skin Tightening in the Upper Inner or Outer Arm (as Measured by Millimeters) — 45.17 millimeters
N/A N=11 Radiofrequency and Pulsed Electromagnetic Field Treatment of Skin Laxity of the Mon Pubis, Labia and Vaginal Introitus
Skin Laxity
Primary: General Skin Appearance of Mons Pubis and Labia — 3; 4; 1 Participants
N/A N=35 Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases
Hernia Repair With Compartment Syndrome
Primary: Hernia Recurrence — 11; 12 percentage of patients
N/A N=45 Ultrasound Assessment of Ventral Hernia Defects
Ventral Incisional Hernia
Primary: Difference in the Shear Wave Velocity Measurements in the Abdominal Wall Between Ventral Hernia and Healthy Abdominal Wall — 1.89; 1.92; 1.89 meters per second
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Phase 2 N=17 Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Hidradenitis Suppurativa · Hidradenitis · Acne Inversa
Primary: Change in Disease Severity — 23.3; 17.7 score on a scale — p=0.042